Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Associations between neuropsychiatric symptoms of affective and vegetative domains and brain morphology in aging people with mild cognitive impairment and Alzheimer's disease

Producción científica: Articlerevisión exhaustiva

2 Citas (Scopus)

Resumen

Objective: Neuropsychiatric symptoms (NPS) are common in mild cognitive impairment (MCI) and even more in Alzheimer's disease (AD). The symptom-based cluster including nighttime disturbances, depression, appetite changes, anxiety, and apathy (affective and vegetative symptoms) was associated with an increased risk of dementia in MCI and has common neuroanatomical associations. Our objective was to investigate the differences in brain morphology associations with affective and vegetative symptoms between three groups: cognitively normal older adults (CN), MCI and AD. Material and Methods: Alzheimer's Disease Neuroimaging Initiative data of 223 CN, 367 MCI and 175 AD, including cortical volumes, surface areas and thicknesses and severity scores of the five NPS were analyzed. A whole-brain vertex-wise general linear model was performed to test for intergroup differences (CN-MCI, CN-AD, AD-MCI) in brain morphology associations with five NPS. Multiple regressions were conducted to investigate cortical change as a function of NPS severity in the AD-MCI contrast. Results: We found (1) signature differences in nighttime disturbances associations with prefrontal regions in AD-MCI, (2) signature differences in NPS associations with temporal regions in AD-MCI for depression and in CN-AD for anxiety, (3) decreased temporal metrics in MCI as nighttime disturbances and depression severity increased, (4) decreased pars triangularis metrics in AD as nighttime disturbances and apathy severity increased. Conclusion: Each NPS seems to have a signature on brain morphology. Affective and vegetative NPS were primarily associated with prefrontal and temporal regions. These signatures open the possibility of potential future assessments of links between brain morphology and NPS on an individual level.

Idioma originalEnglish
Número de artículoe5952
PublicaciónInternational Journal of Geriatric Psychiatry
Volumen38
N.º6
DOI
EstadoPublished - jun 2023

Nota bibliográfica

Publisher Copyright:
© 2023 John Wiley & Sons Ltd.

Financiación

This work was supported by a doctoral research scholarship Centre de recherche de l’Institut Universitaire de Gériatrie de Montréal (CRIUGM)—Volet B in collaboration with NiEmoLab and a Faculty of Medicine of the Université de Montréal merit scholarship given to Lucas Ronat, a doctoral research scholarship Centre de Recherche de l’Institut Universitaire de Gériatrie Montréal (CRIUGM)—Volet B in collaboration with NiEmoLab and a research bursary from NiEmoLab given to Lyna Mariam El Haffaf, as well as funding from the Parkinson Canada-Parkinson Quebec (2018-00355); IUGM Foundation; Fonds de Recherche du Québec Santé; Lemaire Foundation given to Alexandru Hanganu. Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH‐12‐2‐0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol‐Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann‐La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health ( www.fnih.org ). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for NeuroImaging at the University of Southern California. This work was supported by a doctoral research scholarship Volet B in collaboration with NiEmoLab and a Faculty of Medicine of the Université de Montréal merit scholarship given to Lucas Ronat, a doctoral research scholarship Volet B in collaboration with NiEmoLab and a research bursary from NiEmoLab given to Lyna Mariam El Haffaf, as well as funding from the Parkinson Canada‐Parkinson Quebec (2018‐00355); IUGM Foundation; ; Lemaire Foundation given to Alexandru Hanganu. Centre de recherche de l’Institut Universitaire de Gériatrie de Montréal (CRIUGM)— Centre de Recherche de l’Institut Universitaire de Gériatrie Montréal (CRIUGM)— Fonds de Recherche du Québec Santé

FinanciadoresNúmero del financiador
Araclon Biotech
Centre de recherche de l’Institut Universitaire de Gériatrie de Montréal
DOD ADNI
IUGM Foundation
Lemaire foundation
Parkinson Canada-Parkinson Quebec
Université de Montréal merit scholarship given2018‐00355
National Institutes of Health (NIH)U01 AG024904
U.S. Department of DefenseW81XWH‐12‐2‐0012
National Institute on Aging
National Institute of Biomedical Imaging and Bioengineering
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Biogen IDEC
DoD Alzheimer's Disease Neuroimaging Initiative
BioClinica Inc.
AbbVie Canada
Fonds de Recherche du Québec-Santé

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • Geriatrics and Gerontology
    • Psychiatry and Mental health

    Huella

    Profundice en los temas de investigación de 'Associations between neuropsychiatric symptoms of affective and vegetative domains and brain morphology in aging people with mild cognitive impairment and Alzheimer's disease'. En conjunto forman una huella única.

    Citar esto